

22 November 2004

Level 14, Cigna House,
40 Mercer Street, PO Box 10-254
Wellington 6001, New Zealand
Phone 64 4 460 4990
Fax 64 4 460 4995
www.pharmac.govt.nz

To All Pharmaceutical Suppliers, Medical Groups and Interested Parties

By facsimile (1 page)

CONSULTATION ON AMENDED TERMS OF LISTING FOR FOLIC ACID, AMILORIDE, SPIRONOLACTONE, CHLOROTHIAZIDE, DEXAMETHASONE, BIODONE, BIODONE FORTE AND BIODONE EXTRA FORTE ON THE PHARMACEUTICAL SCHEDULE

Community Supply

PHARMAC has reached provisional agreement with Biomed for amended terms of listing in Section B of the Pharmaceutical Schedule for the following pharmaceuticals from 1 January 2005. All pharmaceuticals would continue to be fully subsidised.

Product	Presentation	Strength	Current price and subsidy	Proposed price and subsidy from 1 January 2005
Folic acid oral liquid	25 mL bottle	50 µg/mL	\$20.05	\$21.05
Amiloride oral liquid	25 mL bottle	1 mg/mL	\$24.95	\$26.20
Spirolactone oral liquid	25 mL bottle	5 mg/mL	\$25.50	\$26.80
Chlorothiazide oral liquid	25 mL bottle	50 mg/mL	\$21.50	\$22.60
Dexamethasone oral liquid	25 mL bottle	1 mg/mL	\$38.00	\$39.90
Biodone methadone oral liquid	200 mL bottle	2 mg/mL	\$6.55	\$6.55
Biodone Forte methadone oral liquid	200 mL bottle	5 mg/mL	\$6.86	\$6.52
Biodone Extra Forte methadone oral liquid	200 mL bottle	10 mg/mL	\$9.50	\$9.50

Prices and subsidies are ex-manufacturer, ex-GST.

The provisional agreement includes protection from tendering for all the pharmaceuticals listed above until 30 June 2008. It also includes protection from reference pricing for the above listed folic acid, amiloride, spironolactone, chlorothiazide and dexamethasone until 30 June 2008.

Hospital supply

The provisional agreement includes the listing of all the pharmaceuticals in the table above in Section H of the Pharmaceutical Schedule, at the prices listed above, from 1 January 2005. The Section H listing includes protection from another brand of each pharmaceutical being awarded Hospital Supply Status until 30 June 2008.

Acceptance of the provisional agreement is subject to consultation and approval by the PHARMAC Board, or Chief Executive under Delegated Authority. If you wish to make comments for the PHARMAC Board or Chief Executive to consider when making its decision, please forward them to Hew Norris at PHARMAC by **4:00pm, Monday, 6 December 2004.**

Yours sincerely



Hew Norris
Therapeutic Group Manager